CalciMedica Inc

For the period ended Jun 30, 2024. Filed Aug 12, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 12, 2024

CALC$1.37-9.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

Common Stock · AdditionalPaid-In · Accumulated · AccumulatedOtherComprehensive · TotalStockholders’
	Shares	Amount	Capital	Deficit	Loss	Equity
Balance—December 31, 2023	5,754,505	$1	$154,218	$(146,064)	$2	$8,157
Stock-based compensation expense	—	—	414	—	—	414
Issuance of common shares from private placement (net of issuance costs)	4,985,610	2	7,903	—	—	7,905
Issuance of warrants in connection with the private placement	—	—	660	—	—	660
Unrealized loss on investments	—	—	—	—	(19)	(19)
Net income	—	—	—	130	—	130
Balance—March 31, 2024	10,740,115	3	163,195	(145,934)	(17)	17,247
Stock-based compensation expense	—	—	486	—	—	486
Issuance of common stock from at-the-market offering (net of issuance costs)	8,950	—	47	—	—	47
Issuance of common stock from exercise of stock options	1,091	—	4	—	—	4
Unrealized gain on investments	—	—	—	—	8	8
Net loss	—	—	—	(3,954)	—	(3,954)
Balance—June 30, 2024	10,750,156	$3	$163,732	$(149,888)	$(9)	$13,838

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit)

(in thousands, except share amounts)

Convertible Preferred Stock · Common Stock · AdditionalPaid-In · Accumulated · TotalStockholders’
Shares · Amount · Shares · Amount · Capital · Deficit · Equity/(Deficit)
Balance—December 31, 2022	84,820,880	$62,071	84,165	$1		$40,402		$(111,707)		$(71,304)
Stock-based compensation expense	—	—	—	—		11,126		—		11,126
Conversion of preferred stock to common stock as a result of Merger	(84,820,880)	(62,071)	2,442,852	—		62,071		—		62,071
Issuance of common stock to Graybug stockholders as a result of Merger and reset to par of $0.0001	—	—	1,571,433		29,218		—		29,218
Issuance of common shares from private placement (net of issuance costs)	—	—	596,363	—		10,340		—		10,340
Conversion of promissory notes into common stock	—	—	590,031	—		3,245		—		3,245
Conversion of Series C-2 warrants into common stock	—	—	80,254	—		442		—		442
Conversion of promissory note warrants into common stock	—	—	152,875	—		841		—		841
Merger transaction costs	—	—	—	—		(4,591)		—		(4,591)
Restricted stock units net settlement	—	—	143,960	—		(297)		—		(297)
Reclassification of warrant liability to equity	—	—	—	—		216		—		216
Net loss	—	—	—	—		—		(19,288)		(19,288)
Balance—March 31, 2023	—	—	5,661,933	$1		$153,013		$(130,995)		$22,019
Stock-based compensation expense	—	—	—	—		463		—		463
Adjustment to purchase accounting	—	—	—	—		3		—		3
Merger transaction costs	—	—	—	—		40		—		40
Net loss	—	—	—	—		—		(6,304)		(6,304)
Balance—June 30, 2023	—	$—	5,661,933	$1		$153,519		$(137,299)		$16,221

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.